Phase 2 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who have been diagnosed with uterine, ovarian, fallopian tube, primary peritoneal, cervical, or vulvar cancer
- People who are planned to receive, or have recently completed, 6 to 9 cycles of a chemotherapy regimen containing paclitaxel and carboplatin or cisplatin (which may also include certain other targeted or immune therapies)
- For one group (Arm C): People who completed the chemotherapy regimen described above within the last 3 months
- People with a general health/activity level rated between 0 and 2 on a standard medical scale, meaning they are fully active to capable of limited self-care (confirm with trial site)
Who may not be able to join:
- People who are unwilling or unable to follow all study requirements
- People who have previously been treated with paclitaxel
- People who had nerve damage (neuropathy) before chemotherapy that requires medication to manage
- People with diabetes where a blood sugar control measurement (HbA1c) is above 7.0
- People with moderate to severe liver disease (confirm with trial site for how this is assessed)
- People with a condition called Raynaud's phenomenon, which affects blood flow to the hands and feet
- People with open or active wounds on their hands or feet
- People with serious, uncontrolled heart rhythm problems
- People with heart disease caused by reduced blood flow to the heart
- People with low blood cell counts below certain levels (confirm with trial site)
- People with liver function test results above certain levels (confirm with trial site)
- People with kidney function test results above certain levels (confirm with trial site)
- People taking blood-thinning medications (other than aspirin)
- People who have had a severe allergic reaction to cilostazol or any of its ingredients
- People who are pregnant or breastfeeding
- People who could become pregnant and are not using a reliable form of contraception, as listed by the trial
- People who are currently incarcerated
- People who are unable to give their own informed consent due to cognitive impairment or another reason
- People with any medical reason that prevents them from taking cilostazol
- People who do not meet the standard medical requirements to receive chemotherapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Susan C Modesitt, Emory University Hospital/Winship Cancer Institute
Phone: 404-727-9578
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Difference in sensation and vibration objective neuropathy scores (Arms A and B); Rates of impaired sensation and vibration on objective neuropathy testing and ≥ Grade 2 neuropathy among patients who recently completed paclitaxel treatment with standard of care treatment protocols (Arm C)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.